Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 1 Study Flow During Follow-Up Period
After drug-eluting stent randomization, patients were randomly allocated in a 1:1 ratio to the triple antiplatelet group (aspirin, clopidogrel, and cilostazol; triple group) or the dual antiplatelet therapy group (aspirin and clopidogrel; standard group) on the basis of a 2-by-2 factorial design. Six-month angiographic and 9-month clinical outcomes were assessed.
|
